Effective and safe NFκB clinical inhibitors are not yet available (11), but there is a specific inhibitor of IRAK1/4 as an effective suppressor of the NFκB signaling pathway, whose cancer selectivity effect was approved in studies on BC cell lines (12). The gene discussed is IRAK1; the disease is cancer.